Human fascioliasis successfully treated with triclabendazole |
| |
Authors: | P. P. Laird J. C. Boray |
| |
Affiliation: | Consultant Physician, Lismore, NSW.;Principal Research Scientist, Eizabeth Macarthur Agricultural Institute, NSW Agriculture, Camden, NSW. |
| |
Abstract: | Fascioliasis, caused by the common liver fluke Fusciolu hepatica , is an endemic infection in sheep and cattle in many parts of Australia. Infections in humans in Australia have been reported infrequently and the most appropriate therapy for human fascioliasis remains to be determined. This case report describes a patient with the infection unsuccessfully treated with multiple high doses of praziquantel, mebendazole or albendazole. The infection was successfully eliminated by the administration of triclabendazole in two single doses of 900 mg (12 mg/kg) two days apart. No side effects were observed after the treatment. Based on our experience and that recently reported in the literature, triclabendazole may be regarded as the drug of choice for the treatment of human fascioliasis. (Aust NZ J Med 1992; 22: 45–47.) |
| |
Keywords: | Human fascioliasis chemotherapy triclabendazole |
|
|